Abstract
Objective: Recent evidence has associated immune and inflammatory changes to cognitive performance in many diseases, including schizophrenia. Since this is a new research field where concepts are not yet solid and new questions and hypothesis are still arising, the present study aimed at summarizing the available clinical data associating schizophrenia, cognition and inflammation/immune function.
Methods: A systematic review of the literature was made by searching the following terms in Medline: “schizophrenia or psychosis or psychotic” AND “inflamm* or immun* or cytokine or IL-* or TNF-* or kynureni* or KYNA”, AND “cognit* or attention or memory or executive function”.
Results: Seventy five papers were identified using the selected terms, and seven papers were included in the review. Papers excluded focused mainly on basic research or other neuropsychiatric disorders.
Conclusions: Recent findings link inflammatory markers to cognition in schizophrenia, suggesting that inflammation is associated with worst cognitive performance. Microglial activation, monoaminergic imbalance, brain abnormalities and the kynurenine pathway are possible mechanisms underlying cognitive impairment in schizophrenia. Clinical trials with addition of immunomodulatory drugs have shown promising results, opening new windows to tackle cognition in schizophrenia.
Keywords: Cognition, immunology, inflammation, schizophrenia.
Current Neuropharmacology
Title:Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review
Volume: 12 Issue: 3
Author(s): Rafael Ribeiro-Santos, Antonio Lucio Teixeira and Joao Vinicius Salgado
Affiliation:
Keywords: Cognition, immunology, inflammation, schizophrenia.
Abstract: Objective: Recent evidence has associated immune and inflammatory changes to cognitive performance in many diseases, including schizophrenia. Since this is a new research field where concepts are not yet solid and new questions and hypothesis are still arising, the present study aimed at summarizing the available clinical data associating schizophrenia, cognition and inflammation/immune function.
Methods: A systematic review of the literature was made by searching the following terms in Medline: “schizophrenia or psychosis or psychotic” AND “inflamm* or immun* or cytokine or IL-* or TNF-* or kynureni* or KYNA”, AND “cognit* or attention or memory or executive function”.
Results: Seventy five papers were identified using the selected terms, and seven papers were included in the review. Papers excluded focused mainly on basic research or other neuropsychiatric disorders.
Conclusions: Recent findings link inflammatory markers to cognition in schizophrenia, suggesting that inflammation is associated with worst cognitive performance. Microglial activation, monoaminergic imbalance, brain abnormalities and the kynurenine pathway are possible mechanisms underlying cognitive impairment in schizophrenia. Clinical trials with addition of immunomodulatory drugs have shown promising results, opening new windows to tackle cognition in schizophrenia.
Export Options
About this article
Cite this article as:
Ribeiro-Santos Rafael, Lucio Teixeira Antonio and Vinicius Salgado Joao, Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review, Current Neuropharmacology 2014; 12(3) . https://dx.doi.org/10.2174/1570159X1203140511160832
DOI https://dx.doi.org/10.2174/1570159X1203140511160832 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
An Outline of the Historical and Clinical Aspects of Catatonic Schizophrenia
Current Psychiatry Reviews Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies PSEN1 Promoter Demethylation in Hyperhomocysteinemic TgCRND8 Mice is the Culprit, not the Consequence
Current Alzheimer Research Valosin Containing Protein Associated Fronto-Temporal Lobar Degeneration:Clinical Presentation, Pathologic Features and Pathogenesis
Current Alzheimer Research Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administred in Alzheimers Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Risk Factors for Cardiovascular Disease in Psoriasis: Relation to Inflammation Assessed by the Severity and Duration of Illness
Inflammation & Allergy - Drug Targets (Discontinued) Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Current Alzheimer Research Prematurely Aged Children: Molecular Alterations Leading to Hutchinson-Gilford Progeria and Werner Syndromes
Current Aging Science An Aβ Sequestration Approach Using Non-Antibody Aβ Binding Agents
Current Alzheimer Research Editorial (Thematic Issue: Mitochondria and Subcellular Organelles as Treatment Targets Against Pathological Conditions)
Current Pharmaceutical Design Neuroprotective Therapy for HIV Dementia
Current HIV Research Protein Misfolding in Disease: Cause or Response?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Protein Aggregation in Alzheimers Disease and Other Neoropathological Disorders
Current Alzheimer Research Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Neuroferritinopathy: Update on Clinical Features and Pathogenesis
Current Drug Targets Neurochemistry Changes Associated with Mutations in Familial Parkinsons Disease
Current Medicinal Chemistry Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders